# Dennis J. Slamon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dennis-j-slamon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 101,606 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 126 |
| i10-index | 346 |
| Last Known Institution | University of California, Los Angeles |
| OpenAlex ID | https://openalex.org/A5015491002 |
| ORCID iD | https://orcid.org/0000-0002-6330-498X |
| Works | 990 |

## Researcher papers

- [Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2](https://scholariq.org/papers/use-of-chemotherapy-plus-a-monoclonal-antibody-against-her2-for-metastatic/)
- [Adjuvant Trastuzumab in HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-trastuzumab-in-her2-positive-breast-cancer/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Cycling cancer persister cells arise from lineages with distinct programs](https://scholariq.org/papers/cycling-cancer-persister-cells-arise-from-lineages-with-distinct-programs/)
- [Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations](https://scholariq.org/papers/guidelines-for-human-epidermal-growth-factor-receptor-2-testing-biologic-and/)
- [Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas](https://scholariq.org/papers/localization-of-human-brca1-and-its-loss-in-high-grade-non-inherited-breast/)
- [Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer](https://scholariq.org/papers/prognostic-and-therapeutic-relevance-of-molecular-subtypes-in-high-grade-serous/)
- [Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab](https://scholariq.org/papers/evaluation-of-clinical-outcomes-according-to-her2-detection-by-fluorescence-in/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.